June 02, 2020: “Sanofi Chief Executive Officer Paul Hudson along with R&D and commercial leaders will provide an overview of Sanofi’s oncology strategy and progress update of its related key products and pipeline programs.
Sanofi’s oncology strategy is focused on four core therapeutic areas with four anchor treatments the company believes have the potential to transform patient care.
The four areas of strategic focus within oncology, including multiple myeloma, skin, lung, and breast cancers. Sanofi’s four anchor oncology treatments include Sarclisa® (isatuximab-irfc), an anti-CD38 monoclonal antibody and Libtayo® (cemiplimab-nwlc), a PD-1 checkpoint inhibitor and the pipeline programs – an investigational anti-CEACAM 5 antibody drug conjugate and SERD (‘859), an investigational oral selective estrogen receptor degrader.
“We are rapidly building momentum with the execution of our oncology strategy, with several developments on both our pipeline and marketed treatments.
Additionally, we are assembling a world-class development and marketing team to support our growth in this core area,” said Hudson. “We believe our efforts and treatments have the potential to make a significant difference in the lives of people living with cancer.”
“We’ve developed a focused oncology strategy, and are making significant clinical progress to support our ambitions,” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi.
“With a deep toolbox of therapeutic platforms enabling us to discover highly differentiated molecules, Sanofi has a tremendous opportunity to continue our momentum and build a sustainable presence in oncology.”
The virtual investor event will be held today from 4:00-5:30 pm CET/10:00-11:30 am EST. Sanofi speakers include:
- Paul Hudson, Chief Executive Officer
- John Reed, Global Head of Research and Development
- Dietmar Berger, Chief Medical Officer and Global Head of Development
- Peter Adamson, Global Head of Development, Oncology
- Alex Zehnder, Global Franchise Head, Oncology”